Details for New Drug Application (NDA): 020951
✉ Email this page to a colleague
NDA 020951 describes TAGAMET HB 200, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the TAGAMET HB 200 profile page.
The generic ingredient in TAGAMET HB 200 is cimetidine. There are twenty-five drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cimetidine profile page.
The generic ingredient in TAGAMET HB 200 is cimetidine. There are twenty-five drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cimetidine profile page.
Summary for 020951
| Tradename: | TAGAMET HB 200 |
| Applicant: | Glaxosmithkline |
| Ingredient: | cimetidine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020951
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | 200MG/20ML | ||||
| Approval Date: | Jul 9, 1999 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
